Device
Tobi Podhaler
Tobi Podhaler is a medical device with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completed
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
NCT02449031
completedphase_4
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
NCT03502070
completedphase_4
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
NCT02178540
Clinical Trials (3)
Showing 3 of 3 trials
NCT02449031
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
NCT03502070Phase 4
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
NCT02178540Phase 4
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3